A PHASE III STUDY OF BOTENSILIMAB + BALSTILIMAB VERSUS BEST SUPPORTIVE CARE IN CHEMO-REFRACTORY UNRESECTABLE COLORECTAL ADENOCARCINOMA: THE BATTMAN TRIAL

Registry ID

CO.33

Source registry

HEALTH_CANADA

Status

Ongoing

Phase

PHASE3

Study type

INTERVENTIONAL

Sponsor

CANADIAN CANCER TRIALS GROUP, CANCER RESEARCH INSTITUTE, QUEEN'S UNIVERSITY

Start date

2025-10-06

Last update

2025-09-17

Conditions

• COLORECTAL ADENOCARCINOMA

Related clinical trials

• A PHASE II STUDY OF PERIOPERATIVE QBECO SITE SPECIFIC IMMUNOMODULATOR (QU BIOLOGICS®) IN PATIENTS WITH METASTATIC COLORECTAL ADENOCARCINOMA WITHIN THE LIVER UNDERGOING RESECTION
• A PHASE III, OPEN-LABEL, MULTICENTER, THREE-ARM, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF COBIMETINIB PLUS ATEZOLIZUMAB AND ATEZOLIZUMAB MONOTHERAPY VS. REGORAFENIB IN PATIENTS WITH PREVIOUSLY TREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC COLORECTAL ADENOCARCINOMA

View on source registry